Visual Health Evaluation of New Designed Blue-blocking Glasses
Launched by BEIJING TONGREN HOSPITAL · May 20, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of blue-blocking glasses designed to help reduce visual fatigue, especially for people who spend a lot of time on electronic devices like computers and smartphones. The trial will evaluate how these glasses affect eye comfort and function by measuring things like eye strain and tear film stability. Participants will wear either the new glasses or regular glasses while using screens, and researchers will compare their eye health indicators before and after using the glasses.
To be eligible for this study, participants must be adults aged 65 to 74, with a specific range of vision correction needs. They should not have any significant eye conditions or recent eye surgeries. Participants will need to agree to complete various eye tests and sign a consent form. If you join the trial, you can expect to help contribute to research that could lead to better eye care solutions for people experiencing visual fatigue.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult population, regardless of gender 2. Refractive error is less than or equal to -2.5D and both eyes achieve corrected visual acuity of 0.8 or higher. 3. Normal intraocular pressure with no organic pathology. 4. No apparent symptoms of dry eye. 5. Willing to cooperate to complete all the tests. 6. Voluntarily signing the informed consent form.
- Exclusion Criteria:
- • 1: Individuals with strabismus and amblyopia exist. 2: Suffering from congenital eye conditions such as congenital cataracts or congenital retinal diseases.
- • 3: Those who have undergone intraocular surgery (such as cataract removal, intraocular lens implantation, etc.).
- • 4: Individuals with refractive media opacity (such as corneal lesions, lens opacity, etc.).
- • 5: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg).
- • 6: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg).
- • 7: Only one eye meets the inclusion criteria. 8: Active corneal infections such as bacterial, fungal, viral, or other acute or chronic anterior segment inflammations.
- • 9: Currently using medications that may lead to dry eye or affect vision and corneal curvature.
- • 10: Other ocular conditions, such as dacryocystitis, eyelid disorders and abnormalities, abnormal intraocular pressure, and glaucoma.
- • 11: Unable to undergo regular eye examinations.
About Beijing Tongren Hospital
Beijing Tongren Hospital, affiliated with Capital Medical University, is a leading medical institution in China known for its comprehensive clinical services and research initiatives. With a strong focus on ophthalmology and a commitment to advancing healthcare through innovative clinical trials, the hospital leverages its expertise in various specialties to contribute to medical knowledge and improve patient outcomes. The institution is dedicated to adhering to the highest ethical standards and regulatory requirements, ensuring the integrity and reliability of its research endeavors. Through collaboration with national and international partners, Beijing Tongren Hospital aims to enhance the quality of care and foster advancements in medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing/China, China
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported